124 related articles for article (PubMed ID: 33997992)
1. Concordance of Exposure Changes Because of Renal Impairment Between Results of Dedicated Renal Impairment Studies and Population Pharmacokinetic Predictions.
Ahmed MA; Kalaria SN; Younis IR
J Clin Pharmacol; 2021 Oct; 61(10):1324-1333. PubMed ID: 33997992
[TBL] [Abstract][Full Text] [Related]
2. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
Mahmood I
Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
[TBL] [Abstract][Full Text] [Related]
3. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
[TBL] [Abstract][Full Text] [Related]
4. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Using Population Pharmacokinetics-Based Virtual Control Groups in Organ Impairment Studies.
Younis IR; Wang F; Othman AA
J Clin Pharmacol; 2024 Jun; 64(6):713-718. PubMed ID: 38346862
[TBL] [Abstract][Full Text] [Related]
6. Effect of Renal Function Impairment on the Pharmacokinetics, Safety, and Tolerability of the Iminosugar Sinbaglustat.
Melchior M; Dingemanse J; Alatrach A; Feldkamp T; Sidharta PN; Géhin M
J Clin Pharmacol; 2021 Jul; 61(7):932-938. PubMed ID: 33368330
[TBL] [Abstract][Full Text] [Related]
7. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.
Yee KL; Li M; Cabalu T; Sahasrabudhe V; Lin J; Zhao P; Jadhav P
J Clin Pharmacol; 2018 Mar; 58(3):364-376. PubMed ID: 29077203
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
[TBL] [Abstract][Full Text] [Related]
10. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
[TBL] [Abstract][Full Text] [Related]
12. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Becka M; Mueck W; Halabi A; Maatouk H; Klause N; Lufft V; Wand DD; Philipp T; Bruck H
Br J Clin Pharmacol; 2010 Nov; 70(5):703-12. PubMed ID: 21039764
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment.
Jin F; Robeson M; Zhou H; Hisoire G; Ramanathan S
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1133-41. PubMed ID: 26526983
[TBL] [Abstract][Full Text] [Related]
14. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
Czock D; Keller F; Seidling HM
Br J Clin Pharmacol; 2012 Jul; 74(1):66-74. PubMed ID: 22242561
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.
Christopher RJ; Morgan ME; Tang Y; Anderson C; Sanchez M; Shanahan W
Clin Ther; 2017 Apr; 39(4):837-848.e7. PubMed ID: 28365033
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.
Yin OQ; Tetsuya K; Miller R
Eur J Clin Pharmacol; 2014 Nov; 70(11):1339-51. PubMed ID: 25168620
[TBL] [Abstract][Full Text] [Related]
18. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
19. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Polepally AR; Badri PS; Eckert D; Mensing S; Menon RM
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):333-339. PubMed ID: 27165046
[TBL] [Abstract][Full Text] [Related]
20. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
Wu W; Ke M; Ye L; Lin C
Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
